EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

被引：0
|
作者：
Martin, M. [1 ]
Eiermann, W. [2 ]
Rugo, H. S. [3 ]
Ettl, J. [4 ]
Hurvitz, S. A. [5 ]
Goncalves, A. [6 ]
Yerushalmi, R. [7 ]
Markova, D. [8 ]
Tudor, I. C. [8 ]
Blum, J. L. [9 ]
Hannah, A. L. [10 ]
Litton, J. K. [11 ]
机构：
[1] Univ Complutense, Inst Invest Sanitaria Gregorio Maranon, Med Oncol, CIBERONC,GEICAM, Madrid, Spain
[2] Interdisziplinares Onkol Zentrum Munchen, Chest Surg, Munich, Germany
[3] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Canc Ctr, San Francisco, CA USA
[4] Tech Univ Munich, Obstet & Gynecol, Klinikum Rechts Isar, Munich, Germany
[5] Univ Calif Los Angeles, Hematol Oncol, Los Angeles, CA USA
[6] Inst Paoli Calmettes, Med Oncol, Marseille, France
[7] Beilinson Med Ctr, Rabin Med Ctr, Med Oncol, Petah Tiqwa, Israel
[8] Pfizer Inc, Biostat, San Francisco, CA USA
[9] Baylor Sammons Canc Ctr, Med Oncol, Dallas, TX USA
[10] Pfizer Inc, Med Oncol, San Francisco, CA USA
[11] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
303P
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [31] OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
    Robson, Mark
    Tutt, Andrew
    Balmana, Judith
    Kaufman, Bella
    Garber, Judy
    Geyer, Charles
    Ford, James
    Sharma, Priyanka
    Stuart, Mary
    Mann, Helen
    Fasching, Peter A.
    CANCER RESEARCH, 2015, 75
  • [32] Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial
    Yu, Y.
    Elmeliegy, M.
    Litton, J. K.
    Tudor, I. C.
    Czibere, A.
    Zheng, J.
    Wang, D. D.
    ANNALS OF ONCOLOGY, 2018, 29 : 97 - 97
  • [33] Survival Outcomes and Efficacy of Platinum in Early Breast Cancer Patients with Germline BRCA1 or BRCA2 Mutation: A Multicenter Retrospective Cohort Study
    Chen, Xi
    Qian, Xiaoyan
    Xiao, Min
    Zhang, Pin
    BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 671 - 682
  • [34] Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
    Litton, J. K.
    Hurvitz, S. A.
    Mina, L. A.
    Rugo, H. S.
    Lee, K-H
    Goncalves, A.
    Diab, S.
    Woodward, N.
    Goodwin, A.
    Yerushalmi, R.
    Roch, H.
    Im, Y-H
    Eiermann, W.
    Quek, R. G. W.
    Usari, T.
    Lanzalone, S.
    Czibere, A.
    Blum, J. L.
    Martin, M.
    Ettl, J.
    ANNALS OF ONCOLOGY, 2020, 31 (11) : 1526 - 1535
  • [35] Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial
    Litton, Jennifer K.
    Hurvitz, Sara A.
    Mina, Lida A.
    Rugo, Hope S.
    Lee, Kyung-Hun
    Goncalves, Anthony
    Diab, Sami
    Woodward, Natasha
    Goodwin, Annabel
    Yerushalmi, Rinat
    Roch, Henri
    Im, Young-Hyuck
    Eiermann, Wolfgang
    Quek, Ruben G.
    Usari, Tiziana
    Lanzalone, Silvana
    Czibere, Akos
    Blum, Joanne L.
    Martin, Miguel
    Ettl, Johannes
    CANCER RESEARCH, 2020, 80 (16)
  • [36] Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany
    Lux, Michael P.
    Decker, Thomas
    Runkel, Eva Diana
    Niyazov, Alexander
    Quek, Ruben G. W.
    Marschner, Norbert
    Harbeck, Nadia
    BREAST CARE, 2022, 17 (01) : 40 - 46
  • [37] OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten
    Runswick, Sarah
    Conte, Pierfranco
    CANCER RESEARCH, 2018, 78 (13)
  • [38] Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations
    Turner, N. C.
    Laird, A. D.
    Telli, M. L.
    Rugo, H. S.
    Mailliez, A.
    Ettl, J.
    Grischke, E. -M.
    Mina, L. A.
    Balmana, J.
    Fasching, P. A.
    Hurvitz, S. A.
    Albacker, L. A.
    Frampton, G. M.
    Chelliserry, J.
    Bycott, P.
    Conte, U.
    Wardley, A. M.
    Robson, M. E.
    ANNALS OF ONCOLOGY, 2019, 30 : 108 - +
  • [39] Comparative study of the efficacy of breast cancer neoadjuvant chemotherapy (NAC) in patients (pts) with BRCA1/2 mutation vs sporadic cancer cases versus pts with a family history but no BRCA1/2 mutation.
    Duhoux, Francois P.
    De Rycke, Yann
    Falcou, Marie-Christine
    Bidard, Francois-Clement
    Kirova, Youlia M.
    Savignoni, Alexia
    Alran, Severine
    Pierga, Jean-Yves
    Asselain, Bernard
    Stoppa-Lyonnet, Dominique
    De La Rochefordiere, Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Germline BRCA1/2 Mutation Status Is Not Associated with Differential Radiation Responsiveness in Patients with Locally Advanced Breast Cancer
    Chapman, B. V.
    Liu, D. D.
    Stecklein, S. R.
    Barrera, A. M. Gutierrez
    Woodward, W. A.
    Sawakuchi, G.
    Arun, B. K.
    Shaitelman, S. F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S42 - S43
12345